Another study, which shows promise, aims to target the epichaperomes network by targeting either Hsp90-incorporating epichapromes with PH-H71 (Zelavespib) or PU-AD (Icapamespib) or GRP94-incorporating epichapromes with PU-WS13.7, 8, 19 Currently, zelavespib and icapamespib have translated to clinic not only in AD but in cancer.8, 20, 21 To date, studies on the safety, tolerability and pharmacokinetics of Icapamespib on healthy nonelderly and elderly subjects support a phase 2 advancement of icapamespib for the evaluation in AD and other neurodegenerative diseases.22 This evidence concerns the gene HSP90AA1 and Alzheimer disease.